Brought to you by 
Lilly buys CoLucid for $960mm; gets back its migraine candidate
08 Sep 2020
Executive Summary
Eli Lilly & Co. is paying $960mm ($46.50 per share in cash, a 36% premium) to acquire headache pain drug development firm CoLucid Pharmaceuticals Inc.
Deal Industry
- Biotechnology
- Pharmaceuticals
Deal Status
- Final
Deal Type
-
Acquisition
- Full Acquisition
- Includes Contract
- Payment Includes Cash
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com